Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections

Open Forum Infect Dis. 2021 Jan 7;8(2):ofab002. doi: 10.1093/ofid/ofab002. eCollection 2021 Feb.

Abstract

Twelve patients were treated with omadacycline (OMC) as part of a multidrug regimen for Mycobacterium abscessus. The majority of infections were of pulmonary origin (7/12; 58.3%). The median (interquartile range) duration of OMC was 6.2 (4.2-11.0) months. Clinical success occurred in 9/12 (75.0%) patients. Three patients experienced a possible adverse effect while on therapy.

Keywords: Mycobacterium abscessus; omadacycline; rapidly growing nontuberculous mycobacteria.